Jie Liu, Xuan Wang, Xiao-Ling Yu, Zhi-Miao Lin, Li-Yan Yuan, Bin Yang
{"title":"三种不同生物制剂对银屑病患者心理健康和健康相关生活质量的影响:对中国患者的重复横断面调查","authors":"Jie Liu, Xuan Wang, Xiao-Ling Yu, Zhi-Miao Lin, Li-Yan Yuan, Bin Yang","doi":"10.1097/jd9.0000000000000343","DOIUrl":null,"url":null,"abstract":"Objective: Psoriasis is a chronic inflammatory systemic disease that severely impacts patients’ quality of life (QoL) and psychological health. While biologics have been shown to be effective in treating psoriatic lesions, thus improving QoL, real-life data regarding such effects remain scant. We administered a repeated cross-sectional survey to assess the effects of 8 weeks of biologics treatment on the QoL and mental health status of patients with moderate-to-severe plaque psoriasis. Methods: From March to May 2022, patients with moderate-to-severe plaque psoriasis were enrolled and treated with biologics in the outpatient clinic at the Dermatology Hospital of Southern Medical University. Assessments were performed before treatment and after 4 and 8 weeks of treatment with biologics. Psoriasis severity, QoL, and mental health status were evaluated using the Psoriasis Area and Severity Index (PASI), Dermatology Life Quality Index (DLQI), 36-Item Short Form Health Survey (SF-36), and Hospital Anxiety and Depression Scale (HADS). A multivariate generalized estimating equations (GEE) analysis was used to account for repeated measures and to determine the effects of treatment duration and type of biological agent on relevant indicators. Results: Among the 78 enrolled patients, the ranges of pretreatment scores were 4.6–46.8 for the PASI, 1–30 for the DLQI, 31.5–100 for the physical component score (PCS) of the SF-36, 16.6–100 for the mental component score (MCS) of the SF-36, 0–15 for the HADS-A, and 0–17 for the HADS-D. After 8 weeks of biologics treatment, 98.7% (77/78) of patients had obtained PASI 75. All assessed scores changed over time (GEE, P < 0.05). Moreover, there were group-by-time interaction effects for the DLQI score (GEE, P = 0.023) and PCS (GEE, P = 0.029). The HADS-A and HADS-D scores were both decreased at week 8 compared with pretreatment values. Correlation analyses revealed that higher DLQI scores were associated with lower levels of QoL and higher levels of anxiety or depression. Conclusion: Biologics are not only effective in the treatment of skin lesions, but also exert beneficial effects upon the QoL and mental health of patients with psoriasis as determined in the short-term assessments conducted in this study.","PeriodicalId":73440,"journal":{"name":"International journal of dermatology and venereology","volume":"6 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Effects of three different biologics on mental health and health-related quality of life in patients with psoriasis: a repeated cross-sectional survey of Chinese patients\",\"authors\":\"Jie Liu, Xuan Wang, Xiao-Ling Yu, Zhi-Miao Lin, Li-Yan Yuan, Bin Yang\",\"doi\":\"10.1097/jd9.0000000000000343\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Objective: Psoriasis is a chronic inflammatory systemic disease that severely impacts patients’ quality of life (QoL) and psychological health. While biologics have been shown to be effective in treating psoriatic lesions, thus improving QoL, real-life data regarding such effects remain scant. We administered a repeated cross-sectional survey to assess the effects of 8 weeks of biologics treatment on the QoL and mental health status of patients with moderate-to-severe plaque psoriasis. Methods: From March to May 2022, patients with moderate-to-severe plaque psoriasis were enrolled and treated with biologics in the outpatient clinic at the Dermatology Hospital of Southern Medical University. Assessments were performed before treatment and after 4 and 8 weeks of treatment with biologics. Psoriasis severity, QoL, and mental health status were evaluated using the Psoriasis Area and Severity Index (PASI), Dermatology Life Quality Index (DLQI), 36-Item Short Form Health Survey (SF-36), and Hospital Anxiety and Depression Scale (HADS). A multivariate generalized estimating equations (GEE) analysis was used to account for repeated measures and to determine the effects of treatment duration and type of biological agent on relevant indicators. Results: Among the 78 enrolled patients, the ranges of pretreatment scores were 4.6–46.8 for the PASI, 1–30 for the DLQI, 31.5–100 for the physical component score (PCS) of the SF-36, 16.6–100 for the mental component score (MCS) of the SF-36, 0–15 for the HADS-A, and 0–17 for the HADS-D. After 8 weeks of biologics treatment, 98.7% (77/78) of patients had obtained PASI 75. All assessed scores changed over time (GEE, P < 0.05). Moreover, there were group-by-time interaction effects for the DLQI score (GEE, P = 0.023) and PCS (GEE, P = 0.029). The HADS-A and HADS-D scores were both decreased at week 8 compared with pretreatment values. Correlation analyses revealed that higher DLQI scores were associated with lower levels of QoL and higher levels of anxiety or depression. Conclusion: Biologics are not only effective in the treatment of skin lesions, but also exert beneficial effects upon the QoL and mental health of patients with psoriasis as determined in the short-term assessments conducted in this study.\",\"PeriodicalId\":73440,\"journal\":{\"name\":\"International journal of dermatology and venereology\",\"volume\":\"6 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-08-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International journal of dermatology and venereology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1097/jd9.0000000000000343\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International journal of dermatology and venereology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/jd9.0000000000000343","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
目的:银屑病是一种严重影响患者生活质量和心理健康的慢性炎性全身性疾病。虽然生物制剂已被证明对治疗银屑病病变有效,从而改善生活质量,但关于这种效果的实际数据仍然很少。我们进行了一项重复的横断面调查,以评估8周生物制剂治疗对中重度斑块型银屑病患者生活质量和心理健康状况的影响。方法:于2022年3月至5月在南方医科大学皮肤病医院门诊招募中重度斑块型银屑病患者,并给予生物制剂治疗。分别在治疗前、生物制剂治疗4周和8周后进行评估。采用银屑病面积及严重程度指数(PASI)、皮肤病生活质量指数(DLQI)、36项简短健康调查(SF-36)和医院焦虑抑郁量表(HADS)评估银屑病严重程度、生活质量和心理健康状况。使用多元广义估计方程(GEE)分析来解释重复测量,并确定治疗时间和生物制剂类型对相关指标的影响。结果:78例入组患者中,PASI预处理评分范围为4.6 ~ 46.8分,DLQI预处理评分范围为1 ~ 30分,SF-36预处理评分范围为31.5 ~ 100分,SF-36预处理评分范围为16.6 ~ 100分,HADS-A预处理评分范围为0 ~ 15分,HADS-D预处理评分范围为0 ~ 17分。经过8周的生物制剂治疗,98.7%(77/78)的患者达到PASI 75。所有评估分数都随时间变化(GEE, P <0.05)。此外,DLQI评分(GEE, P = 0.023)和PCS (GEE, P = 0.029)存在分组-时间交互效应。与预处理值相比,HADS-A和HADS-D评分在第8周均下降。相关分析显示,DLQI得分越高,生活质量水平越低,焦虑或抑郁水平越高。结论:生物制剂不仅能有效治疗皮肤病变,而且对银屑病患者的生活质量和心理健康也有有益的影响,这是本研究短期评估的结果。
Effects of three different biologics on mental health and health-related quality of life in patients with psoriasis: a repeated cross-sectional survey of Chinese patients
Objective: Psoriasis is a chronic inflammatory systemic disease that severely impacts patients’ quality of life (QoL) and psychological health. While biologics have been shown to be effective in treating psoriatic lesions, thus improving QoL, real-life data regarding such effects remain scant. We administered a repeated cross-sectional survey to assess the effects of 8 weeks of biologics treatment on the QoL and mental health status of patients with moderate-to-severe plaque psoriasis. Methods: From March to May 2022, patients with moderate-to-severe plaque psoriasis were enrolled and treated with biologics in the outpatient clinic at the Dermatology Hospital of Southern Medical University. Assessments were performed before treatment and after 4 and 8 weeks of treatment with biologics. Psoriasis severity, QoL, and mental health status were evaluated using the Psoriasis Area and Severity Index (PASI), Dermatology Life Quality Index (DLQI), 36-Item Short Form Health Survey (SF-36), and Hospital Anxiety and Depression Scale (HADS). A multivariate generalized estimating equations (GEE) analysis was used to account for repeated measures and to determine the effects of treatment duration and type of biological agent on relevant indicators. Results: Among the 78 enrolled patients, the ranges of pretreatment scores were 4.6–46.8 for the PASI, 1–30 for the DLQI, 31.5–100 for the physical component score (PCS) of the SF-36, 16.6–100 for the mental component score (MCS) of the SF-36, 0–15 for the HADS-A, and 0–17 for the HADS-D. After 8 weeks of biologics treatment, 98.7% (77/78) of patients had obtained PASI 75. All assessed scores changed over time (GEE, P < 0.05). Moreover, there were group-by-time interaction effects for the DLQI score (GEE, P = 0.023) and PCS (GEE, P = 0.029). The HADS-A and HADS-D scores were both decreased at week 8 compared with pretreatment values. Correlation analyses revealed that higher DLQI scores were associated with lower levels of QoL and higher levels of anxiety or depression. Conclusion: Biologics are not only effective in the treatment of skin lesions, but also exert beneficial effects upon the QoL and mental health of patients with psoriasis as determined in the short-term assessments conducted in this study.